SEC Form 4 · accession 0001445064-15-000172
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Matthew K Harbaugh
Officer — Sr. VP & CFO
Period of report
Dec 3, 2015
Accepted (ET)
Dec 7, 2015 · 9:01 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Dec 3, 2014 | P | 260 | $74.046 | A | 46,055 | D | |
| Ordinary SharesF1 | Dec 4, 2015 | P | 240 | $73.54 | A | 46,295 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $73.525 to $73.5503, inclusive. Mr. Harbaugh will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the range.